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Many signals that cause apoptotic cell death operate
by inducing transcription and translation of other (pre-
sumably death effector) mediators, and it is well estab-
lished that stimulus-induced apoptosis can often be
blocked by inhibiting transcription and translation.
Transcriptional regulation of apoptosis, however, is in-
completely understood. To gain insight into nuclear
events associated with signal-induced apoptosis during
T cell development, we studied signal-induced apoptosis
of ex vivo isolated immature CD8141 double-positive
(DP) thymocytes. Stimuli utilizing the T cell receptor
(TCR) signaling pathway or its parts (an aCD3/TCR
monoclonal antibody, a Ca21 ionophore, or a protein
kinase C-activating phorbol ester) or a stimulus that
antagonizes TCR signaling and apoptosis in T cell hybri-
doma (forskolin, a cyclic AMP-signaling activator) re-
sulted in massive apoptosis of DP thymocytes. At the
same time, these stimuli induced qualitatively similar
but quantitatively unique patterns of inducible tran-
scription factors (TFs) NF-kB/RelA-p50, AP-1 (Fos-Jun),
and NUR-77. We focused our attention on the role of
AP-1 (Fos-Jun) complex, which was strongly induced by
all of the above stimuli and thus was a candidate for a
proapoptotic TF. However, we found that AP-1/c-Fos in-
duction was vital in prolonging DP thymocyte life, as
judged by increased spontaneous and induced death of
DP cells in Fos2/2 mice. In direct support of this hypoth-
esis, experiments with antisense oligonucleotides dem-
onstrated that c-Fos plays an essential role in protecting
normal DP thymocytes from Ca21- and cAMP-induced
apoptosis but not from TCR-mediated death. Together,
these results demonstrate a physiological role for c-Fos
in maintaining longevity of DP thymocytes.
Apoptosis plays a key role in tissue modeling during normal
development, yet many of its features remain obscure. One
such feature is the transcriptional control of apoptosis. Signal-
induced apoptosis is an active process that by definition re-
quires transcription and translation (1). Such is the case in
mature T cells, where a primary signaling cascade (e.g. the one
initiated via the TCR1 in T cells) would activate transcription of
the genes whose products function in a secondary, “death ef-
fector” signaling, many of which belong to the TNF family
(TNF, FasL, CD30L, etc.) (2). There is, however, a paucity of
information concerning nuclear (transcriptional) changes that
occur during initial phases of signal-induced apoptosis in other
systems, and it is not clear whether the rule of primary-sec-
ondary cascades applies as well.
One of the most investigated models of apoptosis is the one
using rodent thymocytes. In the steady-state adult murine
thymus, apoptosis daily eliminates up to a third of all thymo-
cytes, or up to 95% of all newly generated cells. The eliminated
cells either failed positive selection (nonselected, or neglected,
cells), or were triggered to die to prevent autoimmunity, be-
cause they bear potentially autoreactive receptors (negative
selection) (3–5). The former type of death corresponds to “pro-
grammed” cell death, because the cells subjected to it, the
CD8141 double-positive (DP) thymocytes, have a strictly lim-
ited life span of 2–3 days in the absence of positive selection (6).
The latter type of death is induced by extracellular signals that
chiefly operate via the TCR and is reminiscent of the activa-
tion-induced cell death (AICD) of mature peripheral T cells
following exposure to antigen (while we shall use the term
AICD for signal-induced apoptosis of thymocytes, it is impor-
tant to bear in mind that the two phenomena are by no means
identical). Experimental apoptosis of thymocytes can be readily
induced in vitro by a variety of stimuli, which utilize different
signaling pathways. Such stimuli include glucocorticoids (glu-
cocorticoid nuclear receptor pathway), ionomycin (an activator
of the Ca21 pathway), PMA (an activator of protein kinase C
and the Ras-Raf pathway), forskolin or prostaglandin E2 (cAMP-
dependent signaling), FasR/CD95 signaling, and g-irradiation
(7–13). Furthermore, negative selection of thymocytes can be
mimicked in vivo and in vitro by agonistic aCD3/TCR-specific
mAbs (10, 14, 15), which, similarly to the natural TCR ligands,
elicit stimulation of the downstream Ca21, protein kinase C,
and other pathways. The bulk of thymocyte apoptosis in these
experimental systems and in the course of in vivo thymocyte
selection (16) occurs among the CD41CD81 DP thymocytes,
precisely because they are the population undergoing selection.
However, relative roles and the interplay of distinct signaling
pathways during physiological development and selection of
thymocytes are poorly understood, as is the role of transcrip-
tional control of the above processes.
To understand the molecular basis of AICD in thymocytes,
we investigated transcription factor (TF) induction and apop-
tosis in DP thymocytes in response to a variety of stimuli
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connected to TCR signaling. We have chosen to follow the
inducible transcription factors of the NF-kB/Rel family (17),
AP-1 (18), NUR-77 (19, 20), and CREB/ATF (21), because their
DNA binding activity was shown to be regulated by signals
inducing cell activation and death. NF-Y (22) was used as a
reference factor with stable DNA binding activity. We describe
a complex pattern of transcription factor induction and provide
evidence for an antiapoptotic role for c-Fos.
EXPERIMENTAL PROCEDURES
Mice—Female C57BL/6 (B6), B6fos2/2 (Jackson Laboratory, Bar
Harbor, ME), and Bcl-2 transgenic mice on B6 background (Ref. 23;
generously provided by Dr. S. Cory, WEHI, Melbourne, Australia, via
Dr. H. T. Petrie, Memorial Sloan-Kettering Cancer Center, New York)
were used at 4–8 weeks of age.
Thymocyte Preparation, Activation, and Flow Cytometry (FCM)—
CD41CD81 DP thymocytes were enriched from total thymocytes by
panning with anti-CD8 mAb (3.155), immobilized on the surface of
plastic dishes, as described previously (24). Alternatively, these cells
and control CD81CD42 were sorted to .99% purity following staining
with directly conjugated anti-CD8 and anti-CD4 mAbs using a FACStar
Plus (Becton Dickinson, Mountain View, CA).
CD41CD81 thymocytes were activated with 10 mg/ml immobilized
anti-CD3e (145–2C11) or soluble anti-Fas mAb (Jo2) (both from PharM-
ingen, San Diego, CA) in 24-well flat-bottom plates. Forskolin (10 mM),
ionomycin (250–1000 ng/ml), PMA (10 ng/ml), dexamethasone (1 mM),
cycloheximide (10 mg/ml), and actinomycin D (200 ng/ml) were pur-
chased from Sigma. Thymocytes were directly stained with excess
FITC-anti-CD8, PE-anti-CD4 (Becton Dickinson, Mountain View, CA)
and FITC-anti-TCRb. FCM analysis was performed on a FACScan flow
cytometer using Lysis II software (Becton Dickinson).
DNA Fragmentation Analysis—This assay was performed as de-
scribed previously (25). Cells were pelleted and resuspended in 0.5 ml of
hypotonic buffer with 0.1% Triton X-100 containing propidium iodide
(PI) (40 mg/ml) and DNase-free RNase A (10 mg/ml). Cells were incu-
bated at 37 °C for 30 min and analyzed by FCM on a FACScan (Becton
Dickinson, CA). The percentage of cells to the left of the diploid G0/1
peak, diagnostic of hypodiploid cells that have lost DNA, was taken as
the percentage of apoptotic cells. Cell viability was also scored by trypan
blue and PI exclusion and was concordant with the degree of apoptosis.
Oligonucleotides and Electrophoretic Mobility Shift Assay (EMSA)—
The following double-stranded oligonucleotides were used in this study
as specific probes for transcription factors (only one strand of a double-
stranded oligonucleotide is shown; binding sites of transcription factors
are underlined; lowercase nucleotides denote ends introduced for unre-
lated cloning purpose): agctTGGGGACTTTCCAGCCG for NF-kB; agct-
TGATGAGTCAGCCG for AP-1; agctCCATGACGTCATGG for CREB;
GGAGTTTTAAAAGGTCATGCTCAATTT for NUR-77; GTCTGAAA-
CATTTTTCTGATTGGTTAAAAGTTGAGTGCT for NF-Y.
Oligonucleotides were end-labeled with [g-32P]ATP using T4 polynu-
cleotide kinase. Nuclear extracts were prepared from 20 3 106 thymo-
cytes unless indicated otherwise. Binding reactions were carried out by
incubating the end-labeled DNA (50,000 cpm) with 2 mg of nuclear
proteins and 2 mg of poly(dI-dC), as described previously (26). For
identification of transcription factors, nuclear extracts were preincu-
bated with 1 ml of specific antiserum for 15 min at 20 °C before the
addition of the labeled oligonucleotide probes. The incubation was con-
tinued for another 30 min and followed by EMSA. Polyclonal rabbit
antisera to the p50 subunit of NF-kB (27), to an N-terminal peptide of
the RelA/p65 subunit of NF-kB (28), to a C-terminal peptide of c-Rel
(29), to mouse RelB, JunB, and JunD (30, 31), and to the full-length
mouse c-Fos (32) and an antiserum to v-Jun that cross-reacts to c-Jun
(33) were kindly provided by Drs. M. Lenardo (NIH, Bethesda, MD), W.
Greene (Gladstone Institute, San Francisco, CA), N. Rice (NCI, Fred-
erick, MD), R. Bravo (Bristol-Myers, Princeton, NJ), T. Curran (Roche
Institute of Molecular Biology, Nutley, NJ) and H. Rahmsdorf (Univer-
sity of Karlsruhe, Germany). Quantification of the band intensity in the
EMSA assay was performed using the Bio-Rad molecular imaging sys-
tem (model GS-250), equipped with Phosphor Analyst software (Bio-
Rad), and is expressed relative to the intensity of bands without stim-
ulation, normalized to the levels of the reference TF, NF-Y.
Northern and Western Analysis—Cytoplasmic cell extracts were used
for isolation and purification of total RNA by the SDS-phenol method.
Total RNA was separated on formaldehyde/MOPS-agarose gel and blot-
ted on Hybond N membranes (Amersham Corp.), which were hybrid-
ized with 32P-labeled DNA probes for GAPDH, Jun-D (34) and c-Fos
(32). Induction of transcription factor mRNA was quantified using the
Bio-Rad molecular imaging system (model GS-250), equipped with
Phosphor Analyst software (Bio-Rad) and is expressed relative to the
level of the reference mRNA for the housekeeping gene, GAPDH.
For Western blot analysis, nuclear proteins were resolved by 10%
SDS-PAGE, transferred to nitrocellulose and processed by a standard
protocol provided in the manufacturer’s manual (Amersham). Poly-
clonal anti-c-Fos antibody was used at 1:1000. Signals were detected
using ECL (Amersham) and were quantified by densitometry.
Antisense Oligonucleotide Treatment—The sense and antisense
phosphorothioate analogues of the oligonucleotides to the 59-end of
c-Fos mRNA including the ATG initiation codon were synthesized (c-
Fos sense oligonucleotide, TCG ACC ATG ATG TTC TCG GGT; c-Fos
antisense oligonucleotide, ACC CGA GAA CAT CAT GCT CCA (35)).
Rel-A sense oligonucleotide (CTG ACC ATG GAC GAT CTG TTT CCC)
was used as another negative control. Purified oligonucleotides were
obtained from the Memorial Sloan-Kettering Cancer Center Micro-
chemistry Core Facility and were used at indicated concentrations. For
all experiments, cells were preincubated for 30 min with oligonucleo-
tides, followed by stimulation with activators for an additional 16 h.
Apoptosis was determined as described.
RESULTS
Signal-induced Apoptosis in DP Thymocytes—To investigate
TF involvement in thymocyte apoptosis, we first established a
model of cortical thymocyte apoptosis. We enriched CD8141
cells to 91 6 2% from total thymocyte suspensions, using pan-
ning with immobilized anti-CD8 mAb (Fig. 1A). The purity of
DP cells could be further increased to 94–96% by the second
round of panning using immobilized anti-CD4 mAb, but such a
treatment, even at 4 °C, had a strong inhibitory effect on tran-
scription factor induction (not shown), reminiscent of its effect
on mature T cell activation (36). Inasmuch as our final goal was
to investigate the relationship between TF induction and
AICD, we avoided extensive CD4 cross-linking and used anti-
CD8 panning in most studies.
As stimuli for AICD, we used full or partial agonists of TCR
signaling (aCD3 mAb, PMA, and ionomycin) and an antagonist
of TCR signaling in T cell hybridomas (forskolin, a cAMP sig-
naling activator). As a positive control, we used dexametha-
sone, an apoptosis-inducing stimulus that operates via the
glucocorticoid nuclear receptor and is not connected directly to
TCR signaling. All of the above stimuli induced extensive
apoptosis in DP thymocytes following overnight treatment, as
determined by quantifying cells with hypodiploid DNA content,
diagnostic for apoptosis (Fig. 1B, lower panels). Cell counting
using trypan blue (optical microscope) or propidium iodide
(FCM) exclusion, confirmed that cell loss was substantial in
each case where the numbers of hypodiploid cells were in-
creased, while that was not the case when few hypodiploid cells
were observed (not shown).
The aim of this work was to investigate whether this apo-
ptosis may be linked to a specific pattern of TF induction. It
was, therefore, important to confirm that all apoptosis in the
above models was indeed due to new transcription and trans-
lation. To that effect, we stimulated DP thymocytes in the
presence of transcription and translation inhibitors actinomy-
cin D (200 ng/ml, not shown) and cycloheximide (10 mg/ml, Fig.
1B, upper traces). As shown in numerous other studies (1,
7–11), we found that apoptosis induced by TCR agonists, for-
skolin, and dexamethasone was inhibited by .90% by actino-
mycin D or cycloheximide and thus was dependent on new
transcription and translation (Fig. 1B). By contrast, FasR-
mediated apoptosis (induced by an agonistic mAb Jo2; Ref. 16)
did not require transcription and translation, consistent with
its rapid kinetics and its proteolytic mechanism of apoptosis
induction (not shown).
By itself, forskolin induced apoptosis in DP thymocytes in a
dose-dependent manner (Fig. 1B and data not shown). Since
forskolin is known to antagonize TCR signaling in hybridomas
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FIG. 1. AICD in enriched CD41CD81 (DP) thymocytes. A, enrichment of DP thymocytes by panning using immobilized anti-CD8 mAbs.
Positively selected thymocytes were directly stained with FITC-anti-CD8 and PE-anti-CD4 mAbs and analyzed by FCM. B, determination of
apoptosis levels by PI staining. DP-enriched thymocytes were treated for 16 h with no stimulus, immobilized anti-CD3e mAb, ionomycin (250
ng/ml), PMA (10 ng/ml), forskolin (10 mM), and dexamethasone (Dex; 1 mM) in the absence (lower traces) or the presence (upper traces) of 10 mg of
cycloheximide (CHX) and assayed for DNA fragmentation by PI staining as described under “Experimental Procedures.” The marker was set to
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(38), we sought to examine whether forskolin may also affect
DP apoptosis regulated by other stimuli. 10 mM forskolin did
not affect PMA- or ionomycin-induced cell death, and, surpris-
ingly, it appeared to synergize with TCR-mediated death of DP
thymocytes (Fig. 1C). These results stand in striking contrast
with the inhibitory effect of forskolin on TCR-dependent apo-
ptosis of a T cell hybridoma (38).2 Thus, the response of T cell
hybridomas, which were routinely used as models of thymocyte
apoptosis, was much closer to the response of mature T cells.
Signal-dependent Activation of Transcription Factors in DP
Thymocytes—We next investigated whether the above stimuli
induced a discernible pattern of TF activation and whether any
of the putative changes in TF activity may be causally related
to AICD of DP thymocytes. For this study, we selected TF AP-1,
NF-kB, and CREB, which are strongly induced in the course of
T cell activation, and the orphan steroid receptor and a puta-
tive TF NUR-77, which is not only induced following activation
but also plays a role in apoptosis (19, 20). As a control, we used
a conserved and constitutively expressed TF NF-Y (22). DP
thymocytes were stimulated for 3 h with the stimuli studied in
Fig. 1, and nuclear extracts from stimulated cells were used to
evaluate the induction of indicated TF by EMSA (Fig. 2A). PMA
(10 ng/ml), PMA plus ionomycin (250 ng/ml), and anti-CD3e
strongly up-regulated the upper NF-kB DNA-binding complex
6–8-, 4-, and 4–5-fold, respectively (as determined by densi-
tometry) and increased the level of the lower complex uni-
formly by about 2-fold. Ionomycin similarly increased the lower
complex (3-fold), but its effects on the upper complex were more
variable: in some experiments (Fig. 2A), this agent only weakly
up-regulated the upper NF-kB complex (1.5-fold), while in oth-
ers the up-regulation of the upper complex was more vigorous
(data not shown). This is consistent with pleiotropic effects of
Ca21 on gene expression and suggests that other, presently
unknown, factors may modulate the effects of Ca21 on tran-
scription factor induction. All of the above stimuli also induced
the AP-1 activity; the upper band was induced 2.5-fold by PMA,
3-fold by ionomycin, 6-fold by their combination, and 3–3.5-fold
by aCD3 (Fig. 2A). NUR-77 DNA binding activity was induced
preferentially by Ca21-inducing stimuli (ionomycin, ionomycin
plus PMA, or anti-CD3, all in the range of 2–3-fold) but not by
PMA alone. Levels and the appearance of CREB/ATF did not
vary very much for ionomycin but were up-regulated by aCD3
and forskolin (data not shown, and Figs. 2B and 3). This, taken
together with the phenotype of the mouse carrying a dominant
negative mutant of CREB/ATF, which does not exhibit discern-
ible defects in T cell development (39), suggested to us that
CREB may not be universally involved in thymocyte apoptosis,
although further experiments are necessary to directly exam-
ine this issue. As expected, the level of the reference transcrip-
tion factor NF-Y was stable (,5% variation), irrespective of
stimulation (Fig. 2A).
cAMP-mediated signaling (forskolin) was shown to induce
apoptosis of immature thymocytes (Ref. 9; Fig. 1C). By con-
trast, cAMP activation antagonized TCR-dependent signaling
in T cell hybridoma and inhibited activation-induced apoptosis
of these cells (38, 40), and we therefore examined the effects of
forskolin on TCR-induced TF activation in DP thymocytes.
Forskolin stimulation of DP thymocytes up-regulated both nu-
clear NF-kB complexes, RelA-p50 and p50-p50, by 1.5–2-fold,
2 Ivanov, V. N., Lee, R. K., Podack, E. R., and Malek, T. R. (1997)
Oncogene 14, in press.
delimit the percentage of apoptotic cells, containing less than the diploid amount of DNA. C, effects of cAMP signaling on activation-induced cell
death. DP thymocytes were activated as indicated for B, in the presence or absence of 10 mM forskolin. Results from at least five different
experiments were used to obtain mean values 6 S.D.
FIG. 2. Transcription factor induction in DP thymocytes by
AICD-promoting stimuli. A and B, induction of TF by TCR-related
signaling. EMSA was performed with nuclear extracts of DP thymo-
cytes stimulated for 3 h with indicated stimuli, at doses detailed in Fig.
1, using labeled oligonucleotide probes for NF-kB, AP-1, NUR-77,
CREB, and NF-Y transcription factors. Quantification of band intensity
relative to basal levels was performed using imaging (see “Experimen-
tal Procedures”).
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as well as AP-1 and NUR-77 (2-fold each) after 3 h (Fig. 2B).
Forskolin also induced the appearance of an additional diffuse
band of CREB with increased mobility (probably a phosphoryl-
ated form of CREB), designed as CREB-P (Fig. 2B). By itself,
aCD3 induced robust RelA-p50 activity (the upper complex was
up-regulated 5-fold) and AP-1 upper complex (Fos-Jun) activity
(3–3.5-fold induction). When administered with aCD3, forsko-
lin decreased anti-CD3-induced levels of RelA-p50 to the levels
induced by forskolin alone, although this effect was less pro-
nounced than the one observed in a T cell hybridoma.2 Like-
wise, forskolin partially suppressed TF binding activities of
AP-1 and NUR-77 induced by aCD3 (Fig. 2B). Thus, although
cAMP signaling partially down-regulated TF activities induced
by anti-CD3, this down-regulation did not result in the sup-
pression of anti-CD3-induced apoptosis of DP thymocytes. In
fact, we observed additive effects of TCR-dependent and cAMP-
dependent signaling in the induction of apoptosis (Fig. 1C). We
conclude that transcriptional regulators different from NF-kB,
NUR-77, and AP-1 are likely to be involved in TCR-mediated
AICD of DP thymocytes but may not operate in mature T cells,
as judged by the behavior of a T cell hybridoma (38, 40).
Enriched DP cells used for the above experiments still con-
tained 8–10% contaminating cells of other phenotypes, the
most abundant (up to 6%) being the CD8142 single-positive. To
control for the effect of this contamination, we performed ex-
periments using .99% pure DP and single-positive CD81CD42
thymocytes (FCM sorting) and showed that NF-kB, AP-1, and
NUR-77 activities could be induced in sorted DP thymocytes
but not in nuclear extracts of CD81 single-positive cells, when
the two were used in the amounts (2 mg and 100 ng, respec-
tively) representative of their ratios present in preparations
obtained by panning (not shown). CREB, however, was present
at relatively high levels following aCD3 induction. Since CREB
is highly inducible in mature T cells, this observation can be
explained by the maturational status of CD81 thymocytes,
which are quite similar to their peripheral counterparts. These
results exclude the role of contaminants in the observed TF
induction, and demonstrate that thymocyte preparations ob-
tained by panning closely approximate the characteristics of
pure DP thymocytes. Therefore, all subsequent experiments
were performed with DP thymocytes enriched by panning.
Identification of TF Induced by TCR Signaling—Competi-
tion experiments with the excess of cold homologous or heter-
ologous oligonucleotides demonstrated the specificity of two
NF-kB DNA-binding complexes, two AP-1 complexes, two
NUR-77 complexes, CREB, and the NF-Y complex (Fig. 3A).
Cross-inhibition was observed with the 32P-AP-1 probe, whose
interaction with nuclear extracts was inhibited not only by the
specific cold oligonucleotide but also by the CREB-binding oli-
gonucleotide (Fig. 3A). This, however, is not surprising, since
the AP-1 and CREB binding sites share considerable homology
and differ by only a single nucleotide. Interestingly, interac-
tions of CREB with its specific site were less sensitive to such
heterologous inhibition, although partial inhibition by the AP-1
oligonucleotide was observed (Fig. 3A).
Positive identification of DNA-binding complexes was
achieved by pretreatment of nuclear proteins with Abs against
specific transcription factors, followed by EMSA. Such treat-
ment results in specific inhibition and/or supershifts of DNA-
binding complexes. Results shown in Fig. 3B, using extracts
from aCD3-stimulated cells, illustrate this type of analysis. As
expected, results indicated that the upper NF-kB complex was
mainly composed of the RelA and p50 (60–70% inhibition with
anti-RelA and 23–25% with anti-p50), while the lower band
contained the NF-kB p50-p50 homodimer (inhibited by .60%
with anti-p50). Neither ionomycin nor forskolin induced nu-
clear RelB or c-Rel activity in DP thymocytes (not shown). By
contrast, PMA (not shown) and anti-CD3 (Fig. 3B) induced
high levels of RelA-p50 (.60% of the upper complex intensity
in Fig. 3B was inhibited with aRelA Ab, as judged by densi-
tometry) and low levels of RelB-p50 (20–25% inhibition by
RelB Ab), which co-migrated as the upper band. No c-Rel ac-
tivity was detected (,5% inhibition).
The upper AP-1 complex is canonically a heterodimer of
Fos-Jun subunits (18), as was clearly shown by inhibiting this
FIG. 3. Identification of transcription factors induced in DP
thymocytes following aCD3-stimulation. A, competition with ho-
mologous and heterologous oligonucleotides. EMSA was performed with
nuclear extracts of aCD3-stimulated DP thymocytes in the presence of
a 250-fold excess of unlabeled oligonucleotides indicated above the
lanes. B, identification of NF-kB and AP-1 DNA-binding complexes.
Nuclear extracts from aCD3-treated DP cells were preincubated with
antisera to NF-kB/RelA, RelB, c-Rel, p50, v-Jun/c-Jun, JunB, JunD, or
c-Fos, as indicated above the lanes, before EMSA, using 32P-kB (left
seven lanes) or 32P-AP-1 (right seven lanes) oligonucleotides. Nonspecific
bands that could be observed after the interaction of labeled probes with
antisera without nuclear extracts are designed nss. Band intensity was
quantified relative to basal levels using imaging (see “Experimental
Procedures”).
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DNA-binding complex with antibodies to Fos (40% inhibition),
JunD (40% inhibition), and JunB (20%). Other Fos family
members (FRA1 and -2) could also have been present. How-
ever, besides c-Fos, JunD, and JunB, the upper AP-1 complex
induced in DP thymocytes surprisingly contained NF-kB RelA
(Fig. 3B). This AP-1 complex did not contain any RelB or c-Rel
activity and, at best, contained only very low amounts of c-Jun
and NF-kB p50. We were able to identify the lower band of the
AP-1 complex from DP thymocytes as a Jun-Jun combination,
containing JunB and JunD (inhibited by specific antibodies by
20–30% and 40%, respectively), but again very little c-Jun (less
than 5% inhibition) (Fig. 3B) (it should be noted that the band
labeled nss denotes a nonspecific complex, which is a result of
interaction of serum proteins and labeled probes, even in the
absence of nuclear proteins). We conclude that stimulation of
DP thymocytes, in addition to Fos-JunD and Fos-JunB com-
plexes, induced a supercomplex of AP-1 and RelA in thymo-
cytes, reminiscent of the one described recently in HeLa cells
(41).
Effect of Antisense c-Fos Oligonucleotide Treatment on In-
duced Levels of Cell Death—All stimuli (ionomycin, PMA, a
combination of PMA and ionomycin, forskolin, and anti-CD3)
induced AP-1/c-Fos TF activity, although PMA alone was not as
consistent and strong an inducer as the other stimuli (not
shown). We next tested whether this induction occurs at the
level of c-Fos mRNA. Northern blot analysis followed by Phos-
phorImager quantification (Fig. 4) showed that c-Fos mRNA
was strongly up-regulated by cAMP and Ca21 signaling but
was at best very weakly induced by aCD3.3 Therefore, tran-
scriptional control of c-Fos expression was stimulus-specific.
To determine whether cell death may be dependent on in-
ducible c-Fos expression and activation, we performed anti-
sense inhibition of c-Fos translation in DP thymocytes, followed
by stimulation of pretreated cells with forskolin, ionomycin,
PMA, or dexamethasone (Fig. 5, A and B). Oligonucleotides at
concentrations used in these experiments were not toxic for DP
thymocytes, since they did not induce necrotic or apoptotic cell
death (Fig. 5 and data not shown). c-Fos suppression by anti-
sense oligonucleotide down-regulated the AP-1 binding activity
(inhibition of the Fos-Jun band by 2.5–3-fold by ionomycin, and
by 1.5–2-fold by forskolin; Fig. 5C), decreased the levels of Fos
protein by 2–2.5-fold as judged by Western blot analysis (Fig.
5D), and specifically increased cell death levels induced by
forskolin (in the oligonucleotide range 0.5–5 mg/ml) and iono-
mycin (1–10 mg/ml) but not by PMA or dexamethasone (Fig.
5A), consistent with the relatively weak induction of c-Fos by
PMA and with the finding that dexamethasone negatively reg-
ulates AP-1-dependent transcription (42). The addition of sense
Fos or sense RelA oligonucleotide had no significant effects on
any of the three parameters examined (Fig. 5). The fact that
c-Fos antisense treatment did not completely block all AP-1
activity and apoptosis likely reflects the activity of other Fos
family members (FRA-1 and FRA-2), which can substitute for
Fos in the upper AP-1 complex. These family members were
shown to substitute for Fos in the Fos2 mice (49, 50). These
results showed that in normal DP thymocytes c-Fos induction
correlated with the protection against Ca21 and cAMP-induced
cell death.
The antiapoptotic protooncogene product Bcl-2 (43, 44) is
developmentally regulated during T cell differentiation (45, 46)
and was implicated in regulating thymocyte survival in vivo
(47), but the mechanism of its action is still obscure. To inves-
tigate whether c-Fos may mediate the antiapoptotic effects of
Bcl-2, we took advantage of Bcl-2 transgenic thymocytes (23).
However, despite blocking c-Fos with antisense oligonucleo-
tides, transgenic Bcl-2 still suppressed DP cell death (Fig. 5B),
3 Note that the values given are calculated relative to the reference
housekeeping gene GAPDH. Hence, although absolute levels of Fos
induced by ionomycin are lower than following aCD3, most probably
owing to strong activation of RNases following ionomycin treatment, its
induction relative to GAPDH is much higher.
FIG. 4. Quantification of the Northern hybridization analysis
of c-Fos and JunD mRNA expression. Two hours following treat-
ment of DP thymocytes with indicated stimuli, total cellular RNA was
isolated and probed as described under “Experimental Procedures” (A).
Intensity of specific bands was quantified by scanning on a Molecular
Imager system (B). Results are presented as percentage of intensity
relative to the levels of a reference housekeeping mRNA, GAPDH.
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indicating that c-Fos was not an essential mediator of Bcl-2-
dependent protection against apoptosis.
DP Thymocytes from fos2/2 Mice Are Hypersensitive to Apo-
ptosis—fos-/- mice exhibit a number of abnormalities, including
prominent bone malformations and a hypoplastic lymphoid
system (48, 49). Their thymocytes were reported to be severely
depleted (48) or normal (50) by two different groups. To eval-
uate the propensity of fos2/2 DP thymocytes to undergo apo-
ptosis, we stimulated them with forskolin, PMA, and dexa-
methasone. These experiments revealed that the absence of
c-Fos leads to a general increase in susceptibility to both spon-
taneous and induced apoptosis (Fig. 6). Increase in spontane-
ous apoptosis, as well as the increase in apoptosis following
stimulation with factors that do not (dexamethasone) or only
slightly (PMA) induce c-Fos, suggest that basal levels of Fos
play a role in protecting from apoptosis. Together, these results
establish c-Fos as an anti-apoptotic factor in DP thymocytes.
DISCUSSION
The most important finding of this study is that, at physio-
logical levels, c-Fos can play an important role in preventing
apoptosis of DP thymocytes in response to Ca21 and cAMP
signaling. These results are supported by the recent elegant
experiments with UV treatment of c-fos2/2 mouse fibroblasts,
which also describe the role for c-Fos in inhibiting apoptosis
(51). Previous observations with the basic phenotype of Fos
knockout mice were initially controversial. One group reported
no alteration of thymic size and weight, whereas the other
reported a severe reduction in thymic size in adult (6-week) but
not neonatal (2-week) animals (50, 48). Subsequent experi-
ments revealed that thymic alterations occurred secondary to
bone abnormalities, which then affected the bone marrow,
since fos2/2 bone marrow cells developed normally into T and B
cells when transferred into normal recipients (48). Overexpres-
sion of transgenic c-Fos also resulted in reduced thymocyte
FIG. 5. Effect of antisense c-Fos oligonucleotide on apoptotic
death of DP thymocytes. Cell death was induced by forskolin, iono-
mycin, PMA, or dexamethasone (Dex) (A) in normal and Bcl-2 trans-
genic (B) mice. DP thymocytes from normal or Bcl-2 transgenic mice
were treated as indicated in the presence of different concentrations of
antisense c-Fos- or sense c-Fos-oligonucleotides, and the representative
results are shown for 10 mg/ml. 18 h after treatment, the percentage of
apoptotic cells was determined by PI staining and flow cytometry.
Significant differences occurring as a consequence of antisense treat-
ment are indicated by the asterisks. C, control EMSA was performed
with nuclear extracts isolated from DP thymocytes 3 h after treatment
with indicated stimuli in the presence and absence of indicated oligo-
nucleotides (10 mg/ml). Treatment by ionomycin or forskolin was per-
formed in separate experiments, and basal levels of AP-1 were different
for these experiments. D, Western blot analysis of Fos protein levels,
using an anti-Fos antibody (Santa Cruz Biotechnology, Santa Cruz,
CA). Results from one experiment, representative of two others, are
shown. Induction and inhibition of complexes for the EMSA assay were
quantified as described for Figs. 2 and 3, while the quantification of
Northern and Western analysis was performed as described under
“Experimental Procedures.”
FIG. 6. fos2/2 mice exhibit an increased sensitivity to sponta-
neous apoptosis and AICD. DP thymocytes from three normal and
three fos2/2 animals were pooled and treated as indicated and were
assayed for apoptosis by FCM at two different time points. Results were
confirmed in another experiment. Dex, dexamethasone.
Transcription Factors in Thymocyte Apoptosis8564
numbers, most likely secondary to a deregulated proliferation
of the thymic epithelium (52). However, spontaneous or stim-
ulus-induced thymocyte apoptosis was never directly investi-
gated in the above knockout and transgenic models. Our re-
sults demonstrate that fos2/2 DP thymocytes do not survive as
well as normal DP cells, providing further evidence for the role
of c-Fos in positively regulating thymocyte survival. In two
other nonlymphoid transformed cell systems, transfection of
chimeric c-Fos was recently shown to induce cell death by
apoptosis (53, 54). Two explanations can be put forward to
reconcile these observations with our results and those of
Schreiber et al. (51). First, it is possible that c-Fos acts in a
tissue-specific and stimulus-specific context to selectively pro-
mote or suppress apoptosis. Our observation that c-Fos did not
prevent all types of DP thymocyte apoptosis is consistent with
this explanation. Second, optimal, but not overexpressed levels
of c-Fos, in concert with other factors, could be necessary for
cell survival. It will be of interest to investigate apoptosis in ex
vivo isolated Fos transgenic thymocytes, since this hypothesis
would predict that an antisense-mediated down-regulation of
c-Fos should protect these thymocytes from apoptosis. Bcl-2 did
not appear to require c-Fos for its protective function. However,
another family member, Bcl-x, is physiologically highly ex-
pressed in DP thymocytes (55), and it will be of interest to
determine the dependence of the antiapoptotic function of this
protooncogene on c-Fos.
Another observation from our study is that AP-1 (Fos-Jun)
presented in the complex with the RelA subunit in activated
DP thymocytes (Fig. 3B). Consistent with this observation,
anti-c-Fos partially suppressed the upper NF-kB complex in-
duced by ionomycin (not shown). The former observation sug-
gested a possible interaction of this complex with AP-1, which
was subsequently confirmed using RelA-specific antibodies. As
was previously shown for HeLa cells (41), this combinatorial
factor is transcriptionally active for the NF-kB-dependent re-
porter constructs. However, the promoter specificity of the AP-
1-RelA complex in vivo, and its connection with the regulation
of cell survival are unknown at present and are currently under
investigation.
Data concerning the AP-1 activity in DP thymocytes are
controversial. Very low levels of both AP-1 DNA binding activ-
ity and AP-1-dependent transcription were observed after ac-
tivation of sorted DP thymocytes (56). Chen and Rothenberg
(57) also concluded that DP thymocytes are characterized by a
strong reduction of AP-1 DNA binding activity. By contrast,
Sen et al. (58) showed that freshly isolated thymocytes con-
tained high levels of AP-1 activity, which dramatically declined
with time following the disruption of the thymocyte-microenvi-
ronment contact. Comparison of the two procedures of thymo-
cyte purification used in our study were consistent with the
latter finding. DP thymocytes enriched by the rapid panning
procedure contained highly inducible AP-1 (Fig. 2), while the
ones isolated by a lengthier FCM sorting (not shown) had
significantly inferior AP-1 inducibility.
Promoter specificity and regulatory activity of the orphan
nuclear receptor NUR-77 are still obscure, but several lines of
evidence have implicated this putative transcription factor (or
a possible negative regulator of transcription factors) in acti-
vation-induced apoptosis of T cell hybridoma (19, 20) and neg-
ative intrathymic selection (59). Results presented here are
consistent with these findings. All stimuli that resulted in
AICD of DP thymocytes induced an early activation of NUR-77
DNA binding activity. It is possible that c-Fos and NUR-77 play
opposite roles in death programs of DP thymocytes, the first
promoting cell survival and the second being important for cell
death control.
Several stimuli investigated in our study strongly activated
NF-kB RelA-p50 complex in DP thymocytes. The NF-kB/Rel
family of TFs controls transcription of many different genes,
including those that play an important role in cell death pro-
grams, such as c-myc and the genes for p53 and TNFa (60–63).
Promoters of the fas-L and fasR genes also contain putative
NF-kB-binding sites (64, 65) although their functional signifi-
cance is unknown. The mechanism of NF-kB activation is based
on the release of RelA-p50 from the cytoplasmic inhibitor IkBa.
This release requires at least two modification steps, IkBa
phosphorylation and proteolysis, the latter probably being me-
diated by cysteine proteases or the proteasome (66, 67). Cys-
teine proteases, especially those from the interleukin-1 con-
verting enzyme (ICE) family, have been implicated as
mediators of many types of apoptotic death (reviewed in Ref.
68). Protease inhibitors are known to antagonize apoptosis (69).
Thus, our data concerning NF-kB activation, which may be
linked to apoptosis, indirectly suggest the possibility that IkBa
processing could be an additional target for the antiapoptotic
function of protease inhibitors. Experiments are currently in
progress to address this possibility.
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